Factors affecting cytochrome P-450 3A activity in cancer patients

Clinical Cancer Research

Volumn 10, Issue 24, 2004, Pages 8341-8350

  Baker, Sharyn D ^a   Van Schaik, Ron H N ^b   Rivory, Laurent P ^c   Ten Tije, Albert J ^b   Dinh, Kimberly ^a   Graveland, Wilfried J ^b   Schenk, Paul W ^b   Charles, Kellie A ^c   Clarke, Stephen J ^d   Carducci, Michael A ^a   McGuire, William P ^e   Dawkins, Fitzroy ^f   Gelderblom, Hans ^g   Verweij, Jaap ^b   Sparreboom, Alex ^h  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c University of Sydney   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e Franklin Square Hospital Center   (United States)

^f HOWARD UNIVERSITY CANCER CENTER   (United States)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYTOCHROME P450 3A;

ADULT; AGED; ARTICLE; BREAST CANCER; BREATH ANALYSIS; DIGESTIVE SYSTEM CANCER; ENZYME ACTIVITY; ERYTHROMYCIN BREATH TEST; FEMALE; GENOTYPE; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; UROGENITAL TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; BODY SIZE; CYTOCHROME P-450 ENZYME SYSTEM; DEMOGRAPHY; DNA, NEOPLASM; FEMALE; HUMANS; ISOENZYMES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; NEOPLASMS; OROSOMUCOID; PHENOTYPE;

EID: 19944427867     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1371     Document Type: Article

References (68)

1. Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst (Bethesda) 2002;94:1883-8.
2. Wilkinson GR. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Hardman JG, Limbird LE, editors. Goodman & Gilmans's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill Medical Publishing Division; 2001. p. 3-29.
3. Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000;10:187-216.
4. Chiou WL, Jeong HY, Wu TC, Ma C. Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization. Clin Pharmacol Ther 2001;70:305-10.
5. Rogers JF, Rocci ML Jr, Haughey DB, Bertino JS Jr. An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity. Clin Pharmacol Ther 2003;73:153-8.
6. Rivory LP, Slaviero KA, Clarke SJ. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer 2002;87:277-80.
7. Mosteller RD. Simplified calculation of body-surface area. N. Engl J Med 1987;317:1098.
8. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Investig 1989;83:688-97.
9. Rivory LP, Slaviero K, Seale JP, et al. Optimizing the erythromycin breath test for use in cancer patients. Clin Cancer Res 2000;6:3480-5.
10. Rivory LP, Slaviero KA, Hoskins JM, Clarke SJ. The erythromycin breath test for the prediction of drug clearance. Clin Pharmacokinet 2001;40:151-8.
11. van Schaik RH, de Wildt SN, van Iperen NM, Uitterlinden AG, van den Anker JN, Lindemans J. CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. Clin Chem 2000;46:1834-6.
12. Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003;74:245-54.
13. Cuzick J. A Wilcoxon-type test for trend. Stat Med 1985;14:445-6.
14. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999;37:485-505.
15. Koch I, Weil R, Wolbold R, et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 2002;30:1108-14.
16. Williams JA, Ring BJ, Cantrell VE, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002;30:883-91.
17. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002;54:1271-94.
18. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91.
19. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11:773-9.
20. Lee SJ, Usmani KA, Chanas B, et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 2003;13:461-72.
21. Amirimani B, Walker AH, Weber BL, Rebbeck TR. RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst (Bethesda) 1999;91:1588-90.
22. Cavaco I, Gil JP, Gil-Berglund E, Ribeiro V. CYP3A4 and MDR1 alleles in a Portuguese population. Clin Chem Lab Med 2003;41:1345-50.
23. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 1999;259:201-5.
24. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001;47:1048-52.
25. Tayeb MT, Clark C, Ameyaw MM, et al. CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics 2000;10:753-6.
26. Garcia-Martin E, Martinez C, Pizarro RM, et al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther 2002;71:196-204.
27. Hamzeiy H, Vahdati-Mashhadian N, Edwards HJ, Goldfarb PS. Mutation analysis of the human CYP3A4 gene 5′-regulatory region: population screening using non-radioactive SSCP. Mutat Res 2002;500:103-10.
28. Paris PL, Kupelian PA, Hall JM, et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomark Prev 1999;8:901-5.
29. Sata F, Sapone A, Elizondo G, et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000;67:48-56.
30. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. CYP3A activity in African-American and European-American men: population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism. Clin Pharmacol Ther 2000;68:82-91.
31. Zeigler-Johnson CM, Walker AH, Mancke B, et al. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered 2002;54:13-21.
32. Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998;95:13176-81.
33. Walker AH, Jaffe JM, Gunasegaram S, et al. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum Mutat 1998;12:289.
34. Lamba JK, Lin YS, Thummel K, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002;12:121-32.
35. Floyd MD, Gervasini G, Masica AL, et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 2003;13:595-606.
36. Ball SE, Scatina J, Kao J, et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′-promoter region of CYP3A4. Clin Pharmacol Ther 1999;66:288-94.
37. Cavaco I, Reis R, Gil JP, Ribeiro V. CYP3A4*1B and NAT2*14 alleles in a native African population. Clin Chem Lab Med 2003;41:606-9.
38. Chelule PK, Gordon M, Palanee T, et al. MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu-Natal, South Africa. Clin Pharmacol Ther 2003;74:195-6.
39. Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 2001;299:825-31.
40. Hsieh KP, Lin YY, Cheng CL, et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 2001;29:268-73.
41. Shih PS, Huang JD. Pharmacokinetics of midazolam and 1′- hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 2002;30:1491-6.
42. Eap CB, Buclin T, Hustert E, et al. Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol 2004;60:231-6.
43. Fukuda T, Onishi S, Fukuen S, et al. CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers. Pharmacogenomics J 2004;4:34-9.
44. Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, Gurney H. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 2004;75:529-38.
45. Goh BC, Lee SC, Wang LZ, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002;20:3683-90.
46. Katz DA, Grimm DR, Cassar SC, et al. CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels. Clin Pharmacol Ther 2004;75:516-28.
47. Bruno R, Vivler N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 1996;24:153-72.
48. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998;16:187-96.
49. Rivory LP, Watkins PB. Erythromycin breath test. Clin Pharmacol Ther 2001;70:395-9.
50. Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000;6:1255-8.
51. Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003;4:224-32.
52. Rudek MA, Sparreboom A, Garrett-Mayer ES, et al. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer 2004;40:1170-8.
53. Baker SD, Grochow LB, Donehower RC. Should anticancer drug doses be adjusted in the obese patient? J Natl Cancer Inst (Bethesda) 1995;87:333-4.
54. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992;44:275-83.
55. Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther 1998;23:247-55.
56. Schwartz JB. Race but not age affects erythromycin breath test results in older hypertensive men. J Clin Pharmacol 2001;41:324-9.
57. Schmucker DL. Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging 2001;18:837-51.
58. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50:222-39.
59. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin. Pharmacokinet 2002;41:329-42.
60. Cummins CL, Wu CY, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 2002;72:474-89.
61. Wolbold R, Klein K, Burk O, et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003;38:978-88.
62. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
63. Schmucker DL, Woodhouse KW, Wang RK, et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 1990;48:365-74.
64. Ioannides C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 2002;32:451-78.
65. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003;35:35-98.
66. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000;18:2505-14.
67. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst (Bethesda) 2002;94:1247-9.
68. Klepser T, Doucette W, Horton H, Buys M, Ernst M, Ford J. Assessment of a patient's perceptions and beliefs regarding herbal therapies. Pharmacotherapy 2000;20:83-7.